{
    "paper_id": "PMC7161509",
    "metadata": {
        "title": "The Renin-Angiotensin-Aldosterone System in Coronavirus Infection \u2013 current considerations during the pandemic",
        "authors": [
            {
                "first": "John",
                "middle": [
                    "G."
                ],
                "last": "Augoustides",
                "suffix": "",
                "email": "yiandoc@hotmail.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "The prevalence of coexisting hypertension has been estimated to be in the (10-25)% range amongst patients presenting with COVID-19.11, 12, 13, 14 The coexisting conditions such as hypertension, older age, diabetes, cardiovascular disease have all been reported to be more common in patients with severe COVID-19 requiring intensive care.14, 15, 16, 17 The comorbidities, including hypertension, have also been significantly associated with adverse outcomes in COVID-19 such as adult respiratory distress syndrome, cardiovascular compromise, and mortality.14, 15, 16, 17, 18\n",
            "cite_spans": [
                {
                    "start": 131,
                    "end": 133,
                    "mention": "11",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 135,
                    "end": 137,
                    "mention": "12",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 139,
                    "end": 141,
                    "mention": "13",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 143,
                    "end": 145,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 337,
                    "end": 339,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 341,
                    "end": 343,
                    "mention": "15",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 345,
                    "end": 347,
                    "mention": "16",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 349,
                    "end": 351,
                    "mention": "17",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 555,
                    "end": 557,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 559,
                    "end": 561,
                    "mention": "15",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 563,
                    "end": 565,
                    "mention": "16",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 567,
                    "end": 569,
                    "mention": "17",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 571,
                    "end": 573,
                    "mention": "18",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "The Prevalence of Exposure to RAAS Inhibitors in Patients with COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "Since the comorbidity of hypertension has been associated with severe COVID-19 and its consequences, the question has emerged about the roles of RAAS inhibitors such as ACEI and ARBS in the pathogenesis of severe COVID-19. Given that these RAAS inhibitors are common therapies for hypertension and that they may up-regulate the expression of ACE2, the clinical concern has been formulated that therapy with these agents may increase the risk and severity of coronavirus infection.19, 20, 21, 22 There is currently insufficient evidence to address this question in a definitive fashion.1\n,\n14 The published literature both in preclinical and clinical studies has conflicting results about the potential for harm with respect to the interactions between RAAS inhibitors and coronavirus 19. Further trials will likely focus on the current evidence gaps related to this question in severe COVID-19 including mechanisms, the prevalence of RAAS inhibitors, and careful correlation of this prevalence with clinical outcomes.1\n,\n18, 19\n",
            "cite_spans": [
                {
                    "start": 480,
                    "end": 482,
                    "mention": "19",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 484,
                    "end": 486,
                    "mention": "20",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 488,
                    "end": 490,
                    "mention": "21",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 492,
                    "end": 494,
                    "mention": "22",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 585,
                    "end": 586,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 589,
                    "end": 591,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1017,
                    "end": 1018,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 1021,
                    "end": 1023,
                    "mention": "18",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1025,
                    "end": 1027,
                    "mention": "19",
                    "ref_id": "BIBREF18"
                }
            ],
            "section": "The Prevalence of Exposure to RAAS Inhibitors in Patients with COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "Although hypertension and consequent exposure to ACEI and ARBS are likely common in severe COVID-19, this association does link to causality, as outlined above.23\n,\n24 There may also be confounding by association here in that patients with severe COVID-19 are more likely to be hypertensive, diabetic and older. This comorbidity burden rather than the associated drug therapy may better explain the adverse outcomes in coronavirus infection.17, 18, 19\n",
            "cite_spans": [
                {
                    "start": 160,
                    "end": 162,
                    "mention": "23",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 165,
                    "end": 167,
                    "mention": "24",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 441,
                    "end": 443,
                    "mention": "17",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 445,
                    "end": 447,
                    "mention": "18",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 449,
                    "end": 451,
                    "mention": "19",
                    "ref_id": "BIBREF18"
                }
            ],
            "section": "Possible Benefits of RAAS Inhibitors in Patients with COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "In contrast, animal studies have clearly documented that ACE2 may have a protective role in acute lung injury related to coronavirus infection.25\n,\n26 Functional ACE2 typically converts angiotensin II to angiotensin 1-7, thereby reducing the adverse effects of angiotensin II via the angiotensin type I receptor in the lung that lead to acute lung injury.1\n,\n21 Since therapy with ACEI and/ot ARBS also reduces angiotensin II levels, it follows that these agents may also protect against acute lung injury in the setting of COVID-19.1\n,\n21\n,\n27\n",
            "cite_spans": [
                {
                    "start": 143,
                    "end": 145,
                    "mention": "25",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 148,
                    "end": 150,
                    "mention": "26",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 355,
                    "end": 356,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 359,
                    "end": 361,
                    "mention": "21",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 533,
                    "end": 534,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 537,
                    "end": 539,
                    "mention": "21",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 542,
                    "end": 544,
                    "mention": "27",
                    "ref_id": "BIBREF26"
                }
            ],
            "section": "Possible Benefits of RAAS Inhibitors in Patients with COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "The evidence for the benefits ACE2 in coronavirus infection has prompted further investigations. The exogenous administration of recombinant ACE2 may not only bind circulating coronavirus to acute viral load but also could degrade angiotensin II to down-regulate activation of the RAAS and protect against acute lung injury in COVID-19.1\n,\n22\n,\n28 This fascinating dual function of ACE2 has prompted a pilot clinical trial to evaluate recombinant ACE2 in patients with COVID-19 (full details available at www.clinicaltrials.gov with trial identifier #NCT04287686, last accessed March 31st 2020). The potential therapeutic effects of ARBS in COVID-19 have also triggered a set of clinical trials (full details available at www.clinicaltrials.gov with trial identifiers #NCT04312009 and #NCT04311177, last accessed March 31st 2020). Furthermore, there are clinical trials in progress investigating the effects of ACEI in patients with COVID-19 (full details available at www.clinicaltrials.gov with trial identifiers #NCT04322786 and #NCT04318418, last accessed March 31st 2020). These trials will likely provide much needed evidence to guide therapy with RAAS inhibitors in patients throughout the clinical spectrum of COVID-19.",
            "cite_spans": [
                {
                    "start": 336,
                    "end": 337,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 340,
                    "end": 342,
                    "mention": "22",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 345,
                    "end": 347,
                    "mention": "28",
                    "ref_id": "BIBREF27"
                }
            ],
            "section": "Possible Benefits of RAAS Inhibitors in Patients with COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "Patients with severe COVID-19 may also develop vasoplegic shock with or without concomitant sepsis.30 In the initial wave of COVID-19 in Seattle, patients with cardiovascular compromise seldom had superinfection, suggesting that the cardiovascular instability was mostly due to the consequences of viral infection.6 Furthermore, in this patient cohort, echocardiography also rarely identified ventricular dysfunction, although myocarditis is a possibility in this disease.30 This latest data from the pandemic in the United States suggests that vasoplegic shock from the effects of the coronavirus is a likely clinical presentation in severe COVID-19.6\n",
            "cite_spans": [
                {
                    "start": 99,
                    "end": 101,
                    "mention": "30",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 314,
                    "end": 315,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 472,
                    "end": 474,
                    "mention": "30",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 651,
                    "end": 652,
                    "mention": "6",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "RAAS Inhibitors and Vasoplegic Shock in COVID -19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "A possible etiology for this low systemic vascular tone in this clinical setting may be the disordered function of the RAAS.1\n,\n21 The first possibility is that patients on ACEI and ARBS may be at greater risk for vasoplegia in the setting of an exaggerated systemic inflammatory response, akin to what we typically observe in perioperative cardiothoracic and vascular practice.4\n,\n5 A second possibility is that the severe alveolar endothelial damage from adult respiratory distress syndrome may disrupt the function of angiotensin-converting enzyme 1, interfering with the hydrolysis of angiotensin I to form angiotensin II.1, 2, 3 The resulting deficiency of angiotensin II leads to loss of systemic vascular tone.2\n,\n3 Furthermore, the resulting excess of angiotensin I also aggravates vasoplegia through the enhanced production of nitric oxide and bradykinin.2\n,\n3 The possibility therefore exists that vasoplegic shock in severe COVID-19 may be due to dysregulation of the renin-angiotensin-aldosterone system with consequent angiotensin II deficiency, suggesting that exogenous administration of this vasopressor may have a unique role in this clinical scenario.2\n",
            "cite_spans": [
                {
                    "start": 124,
                    "end": 125,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 128,
                    "end": 130,
                    "mention": "21",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 378,
                    "end": 379,
                    "mention": "4",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 382,
                    "end": 383,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 626,
                    "end": 627,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 629,
                    "end": 630,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 632,
                    "end": 633,
                    "mention": "3",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 717,
                    "end": 718,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 721,
                    "end": 722,
                    "mention": "3",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 864,
                    "end": 865,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 868,
                    "end": 869,
                    "mention": "3",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1169,
                    "end": 1170,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "RAAS Inhibitors and Vasoplegic Shock in COVID -19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "The status quo with respect to ACEI and ARBS in COVID-19 can be confusing to clinicians in the front lines of patient care during the pandemic, given the possibilities for both benefit and harm.14\n,\n15 This priority for clinical guidance during the coronavirus virus has prompted recent statements from multiple professional societies including the Canadian Cardiovascular Society, the European Society of Hypertension, the International Society of Hypertension, the European Society of Cardiology and American College of Cardiology.13\n,\n14 In summary, the expert consensus from all these professional societies is that patients with COVID-19 should continue their regular home blood antihypertensive regimen, even if it includes ACEI and ARBS.14 In patients with COVID-19 who develop shock, the vasodilator regimen with RAAS inhibitors can be discontinued.14\n",
            "cite_spans": [
                {
                    "start": 194,
                    "end": 196,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 199,
                    "end": 201,
                    "mention": "15",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 533,
                    "end": 535,
                    "mention": "13",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 538,
                    "end": 540,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 744,
                    "end": 746,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 857,
                    "end": 859,
                    "mention": "14",
                    "ref_id": "BIBREF13"
                }
            ],
            "section": "Navigating the Present Status Quo with RAAS Inhibitors and COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "Although not specifically addressed in these multiple professional guidelines, the roles of rescue therapy for vasoplegic shock can also be considered in refractory cases, including angiotensin II.2\n,\n4\n,\n5 Furthermore, in treatment-resistant cases of COPVID-19, the mechanisms for cardiogenic shock and the supportive roles of extracorporeal membrane oxygenation should be entertained early, as these considerations can often lead to therapeutic breakthroughs.29, 30, 31\n",
            "cite_spans": [
                {
                    "start": 197,
                    "end": 198,
                    "mention": "2",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 201,
                    "end": 202,
                    "mention": "4",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 205,
                    "end": 206,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 461,
                    "end": 463,
                    "mention": "29",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 465,
                    "end": 467,
                    "mention": "30",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 469,
                    "end": 471,
                    "mention": "31",
                    "ref_id": "BIBREF30"
                }
            ],
            "section": "Navigating the Present Status Quo with RAAS Inhibitors and COVID-19 ::: Introduction",
            "ref_spans": []
        },
        {
            "text": "The spectrum of severe COVID-19 includes significant disruption of the RAAS, with significant implications for organ dysfunction, vascular tone, as well as therapy with ACEI and ARBS. Although clinical trials are in progress to close the current evidence gaps, the current expert consensus has recommended that in most cases, existing therapy with ACEI and ARBS be continued. In the setting of circulatory shock, these agents may be discontinued and early consideration of therapies for medical and mechanical rescue may be lifesaving. The management of patients through this pandemic must also consider infection control to prevent further viral transmission.",
            "cite_spans": [],
            "section": "Conclusions",
            "ref_spans": []
        },
        {
            "text": "None",
            "cite_spans": [],
            "section": "Conflicts of Interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Vaduganathan",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Vardeny",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Michel",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Angiotensin II for the treatment of COVID-19-related vasodilatory shock",
            "authors": [
                {
                    "first": "J.H.",
                    "middle": [],
                    "last": "Chow",
                    "suffix": ""
                },
                {
                    "first": "M.A.",
                    "middle": [],
                    "last": "Mazzeffi",
                    "suffix": ""
                },
                {
                    "first": "M.T.",
                    "middle": [],
                    "last": "McCurdy",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Anesth Analg",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "The vasoactive Mas receptor in essential hypertension",
            "authors": [
                {
                    "first": "A.L.",
                    "middle": [],
                    "last": "Povisen",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Grimm",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Wehland",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Med",
            "volume": "9",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Vasoplegia during cardiopulmonary bypass: current literature and rescue therapy options",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Ortoleva",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Shapeton",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Vanneman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Cardiothorac Vasc Anesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Vasoplegia after cardiovascular procedures \u2013 pathophysiology and targeted therapy",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Shaefi",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "MIttel",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Klick",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Cardiothorac Vasc Anesth",
            "volume": "32",
            "issn": "",
            "pages": "1013-1022",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "COVID-19 in critically ill patients in the Seattle region \u2013 case series",
            "authors": [
                {
                    "first": "P.K.",
                    "middle": [],
                    "last": "Bhatraju",
                    "suffix": ""
                },
                {
                    "first": "B.J.",
                    "middle": [],
                    "last": "Ghassemieh",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Nichols",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",
            "authors": [
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Outbreak of a new coronavirus: what anaesthetists should know",
            "authors": [
                {
                    "first": "P.W.H.",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "P.L.",
                    "middle": [],
                    "last": "Ho",
                    "suffix": ""
                },
                {
                    "first": "S.S.",
                    "middle": [],
                    "last": "Hota",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Brit J Anaesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Chinese Society of Anesthesiologists expert consensus on anesthetic management of cardiac surgical patients with suspected or confirmed coronavirus disease 2019",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Bian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Cardiothorac Vasc Anesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Anesthetic management of patients undergoing aortic dissection repair with suspected severe acute respiratory syndrome Coronavirus-2 infection",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Cardiothorac Vasc Anesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Clinical characteristics of coronavirus disease 2019 in China",
            "authors": [
                {
                    "first": "W.J.",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z.Y.",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Clinical features of patients with 2019 novel coronavirus in Wuhan",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Lancet",
            "volume": "395",
            "issn": "",
            "pages": "497-506",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic",
            "authors": [
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Driggin",
                    "suffix": ""
                },
                {
                    "first": "M.V.",
                    "middle": [],
                    "last": "Madhavan",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Bikdeli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Potential effects of coronaviruses on the cardiovascular system: a review",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Madjid",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Safavi \u2013Naeini",
                    "suffix": ""
                },
                {
                    "first": "S.D.",
                    "middle": [],
                    "last": "Solomon",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA Cardiol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "CSC expert consensus on principles of clinical management of patients with severe emergent cardiovascular disease during the COVID-19 epidemic",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Circulation",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Coronavirus disease 2019 (COVID-19) and cardiovascular disease",
            "authors": [
                {
                    "first": "K.J.",
                    "middle": [],
                    "last": "Clerkin",
                    "suffix": ""
                },
                {
                    "first": "J.A.",
                    "middle": [],
                    "last": "Fried",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Raihelkar",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Circulation",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "COVID-19 and the cardiovascular system",
            "authors": [
                {
                    "first": "Y.Y.",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y.T.",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "J.Y.",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Cardiol",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Coronaviruses and the cardiovascular system: acute and long-term implications",
            "authors": [
                {
                    "first": "T.Y.",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Redwood",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Prendergast",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Heart J",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Esler",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Esler",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Hypertens",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?",
            "authors": [
                {
                    "first": "G.M.",
                    "middle": [],
                    "last": "Kuster",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Pfister",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Burkhard",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Heart J",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19",
            "authors": [
                {
                    "first": "J.H.",
                    "middle": [],
                    "last": "Diaz",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Travel Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Ya.",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Gou",
                    "middle": [],
                    "last": "Xi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Infect Dis",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis",
            "authors": [
                {
                    "first": "W.J.",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "Y.I.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Resp J",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Angiotensin-converting enzyme 2 protects from severe acute lung failure",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nature",
            "volume": "436",
            "issn": "",
            "pages": "112-116",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Kuba",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "RAo",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Mat Ned",
            "volume": "11",
            "issn": "",
            "pages": "875-879",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Gurwitz",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Drug Dev res",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Penninger",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Intensive Care Ned",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Cardiovascular consequences and considerations of coronavirus infection \u2013 perspectives for the cardiothoracic anesthesiologist and intensivist during the coronavirus crisis",
            "authors": [
                {
                    "first": "J.G.",
                    "middle": [],
                    "last": "Augoustides",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Cardiotrhorac Vasc Anesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Management strategies for severe and refractory acute respiratory distress syndrome: where do we stand in 2018?",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Nasim",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Sukhal",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Ramakrishna",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Cardiothorac Vasc Anesth",
            "volume": "33",
            "issn": "",
            "pages": "2589-2594",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Extracorporeal membrane oxygenation \u2013 crucial considerations during the coronavirus crisis",
            "authors": [
                {
                    "first": "J.G.",
                    "middle": [],
                    "last": "Augoustides",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Cardiotrhorac Vasc Anesth",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}